New prescribing criteria for Mounjaro (Tirzepatide)

What’s Changing?

From 23 June, the prescribing of Mounjaro (Tirzepatide) will start to become available for weight loss purposes through General Practice.

This does not mean prescriptions will be immediately available, as neither Semaglutide (Wegovy) or Tirzepatide (Mounjaro) injections are currently available on NHS supply in Hampshire.

Once there are NHS prescription supplies to support weight loss, they will only be available for a small, specific group of patients based on a specific qualifying criteria as follows:

Patients must have a BMI equal to or over 40 as well as 4 confirmed diagnoses of the following 5 health related problems:

Type 2 Diabetes

Hypertension

Dyslipidaemia

Cardiovascular Disease

Obstructive sleep apnoea

A patient who meets the NHS priority criteria (above) should be able to access a prescribing pathway in a primary care (GP) setting, if both patient and clinician agree it is the most appropriate treatment option once readily available. Further information can be found at www.hantsiow.icb.nhs.uk/weight-loss-support

We will update this page and share new information as soon as these become available.